mCRPC VL

Treatment of mCRPC

Details
Treatment of Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Bryan Mehlhaff, MD discusses the treatment history of a 49-year-old prostate cancer patient from the time of diagnosis through 2012. Bryan A. Mehlhaff, MD Oregon Urology Institute

Immunotherapy in CRPC - James Gulley

Details
Immunotherapy Castration-resistant Prostate Cancer: What do we know and Clinical Applications Dr. James Gulley discusses immunotherapy for prostate cancer, including how therapeutic vaccines work, examples of therapeutic vaccines in mCRPC, appropriate patient populations to treat with immunotherapy, and immune checkpoint inhibitors. James L. Gulley, MD, PhD, FACP - BIO